RxDoctor Payments Data

Gurtej Malhi, MD

Gastroenterology · Stockton, CANPI 1174934897

Payments from drug & device makers

$3,472in general payments, 2019–2025

Across 65 payments — averaging $53.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ovesco Endoscopy USA, Inc.$1K
  • Boston Scientific$1K
  • Olympus Corporation Of The Americas$594
  • AbbVie$274
  • Gilead$161
  • Endogastric Solutions, Inc$77
  • plus $116 from 3 others

What the payments were for

  • Travel & lodging$2,00058%
  • Food & beverage$1,47342%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,472 in reported general payments places this provider in the 55th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$232,096
Medicare patients
592
Services billed
1,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib28$188,708
CreonLipase/Protease/Amylase53$101,195
Humira(Cf) PenAdalimumab12$79,948
VemlidyTenofovir Alafenamide15$21,745
Mesalamine22$14,560
Ursodiol37$4,129
Sucralfate30$2,282
Dicyclomine Hcl88$2,265
Omeprazole99$1,916
Balsalazide Disodium12$1,776
Pantoprazole Sodium50$989
Entecavir13$708
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl30$501
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl14$261
Spironolactone23$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon$274$289,90381 claims
GileadVemlidy$161$21,74515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →